RU2007128062A - A-7 NICOTINE RECEPTOR LIGANDS, THEIR PRODUCTION AND APPLICATION - Google Patents
A-7 NICOTINE RECEPTOR LIGANDS, THEIR PRODUCTION AND APPLICATION Download PDFInfo
- Publication number
- RU2007128062A RU2007128062A RU2007128062/04A RU2007128062A RU2007128062A RU 2007128062 A RU2007128062 A RU 2007128062A RU 2007128062/04 A RU2007128062/04 A RU 2007128062/04A RU 2007128062 A RU2007128062 A RU 2007128062A RU 2007128062 A RU2007128062 A RU 2007128062A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- azabicyclo
- oct
- indazole
- carboxylic acid
- Prior art date
Links
- 0 C*=C1C(C(OC2C(CC3)C3CCNC2)=O)=N*C1=C Chemical compound C*=C1C(C(OC2C(CC3)C3CCNC2)=O)=N*C1=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the alpha7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Claims (53)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63777104P | 2004-12-22 | 2004-12-22 | |
US60/637,771 | 2004-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007128062A true RU2007128062A (en) | 2009-01-27 |
RU2418797C2 RU2418797C2 (en) | 2011-05-20 |
Family
ID=36177987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007128062/04A RU2418797C2 (en) | 2004-12-22 | 2005-12-21 | LIGANDS OF NICOTINE RECEPTOR α, THEIR OBTAINING AND APPLICATION |
Country Status (15)
Country | Link |
---|---|
US (2) | US7625924B2 (en) |
EP (1) | EP1828179B1 (en) |
JP (1) | JP2008525464A (en) |
KR (1) | KR20070087674A (en) |
CN (1) | CN101124224A (en) |
AT (1) | ATE455776T1 (en) |
AU (1) | AU2005319248A1 (en) |
BR (1) | BRPI0517494A (en) |
CA (1) | CA2591817A1 (en) |
DE (1) | DE602005019094D1 (en) |
ES (1) | ES2342675T3 (en) |
MX (1) | MX2007007328A (en) |
PL (1) | PL1828179T3 (en) |
RU (1) | RU2418797C2 (en) |
WO (1) | WO2006069097A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780981B2 (en) | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
JP2010523587A (en) * | 2007-04-02 | 2010-07-15 | パーキンソンズ インスティテュート | Methods and compositions for reducing the side effects of therapeutic treatments |
SA08290475B1 (en) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof |
US8114891B2 (en) * | 2007-10-01 | 2012-02-14 | Comentis, Inc. | 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof |
CA2728451C (en) * | 2008-08-12 | 2013-09-24 | F. Hoffmann-La Roche Ag | Salicylamide derivatives as nicotinic alpha 7 modulators |
JP5425915B2 (en) * | 2008-10-13 | 2014-02-26 | エフ.ホフマン−ラ ロシュ アーゲー | Method for producing diazonium-free indazole intermediate in the synthesis of bicyclic 5- (trifluoromethoxy) -1H-3-indazolecarboxylic acid amide |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
TWI558398B (en) | 2009-09-22 | 2016-11-21 | 諾華公司 | Use of nicotinic acetylcholine receptor alpha 7 activators |
US20110172428A1 (en) | 2010-01-12 | 2011-07-14 | Shan-Ming Kuang | Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt |
RU2573293C2 (en) | 2010-03-26 | 2016-01-20 | Филип Моррис Продактс С.А. | Inhibition of irritating sensations in process of non-smoking tobacco products consumptions |
US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
WO2011133858A2 (en) | 2010-04-23 | 2011-10-27 | University Of Florida Research Foundation, Inc. | Compositions, methods of use, and methods of treatment |
US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
US8242276B2 (en) | 2010-06-30 | 2012-08-14 | Hoffmann-La Roche Inc. | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt |
KR101928505B1 (en) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | Pharmaceutical composition comprising pyridone derivatives |
EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Compositions and methods for treatment of symptoms in parkinson's disease patients |
WO2013116413A1 (en) * | 2012-02-02 | 2013-08-08 | Targacept, Inc. | Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
US20170166561A1 (en) | 2014-07-11 | 2017-06-15 | Alpharmagen, Llc | Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
CA2977814A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
WO2016201096A1 (en) * | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
JP7420797B2 (en) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | Drug delivery methods and systems |
CN111808907B (en) * | 2019-10-09 | 2021-07-09 | 北京原基华毅生物科技有限公司 | Materials and methods for modulating wakefulness |
WO2023230540A2 (en) * | 2022-05-25 | 2023-11-30 | Katholieke Universiteit Leuven | Indazole derivatives for treating trpm3-mediated disorders |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL59004A0 (en) | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
FR2531083B1 (en) | 1982-06-29 | 1986-11-28 | Sandoz Sa | NOVEL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES |
JPS5936675A (en) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | Cyclic carboxylic acid piperidyl ester and amide derivative |
FR2548666A1 (en) | 1983-07-08 | 1985-01-11 | Delalande Sa | New nortropane and granatane derivatives, process for their preparation and their application in therapeutics |
CH664567A5 (en) | 1983-08-26 | 1988-03-15 | Sandoz Ag | AROMATIC CARBONIC ACID AND SULPHONIC ACID ESTERS OR AMIDES. |
US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
DE3687080T2 (en) | 1985-04-27 | 1993-03-25 | Beecham Group Plc | AZABICYCLONONYL INDAZOL CARBOXAMIDE WITH 5-HT ANTAGONISTIC EFFECT. |
US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
GB8623142D0 (en) | 1986-09-26 | 1986-10-29 | Beecham Group Plc | Compounds |
GB8518658D0 (en) | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Medicaments |
US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
GB8520616D0 (en) | 1985-08-16 | 1985-09-25 | Beecham Group Plc | Compounds |
IN166416B (en) | 1985-09-18 | 1990-05-05 | Pfizer | |
GB8525844D0 (en) * | 1985-10-19 | 1985-11-20 | Beecham Group Plc | Compounds |
US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
HU202108B (en) | 1986-07-30 | 1991-02-28 | Sandoz Ag | Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol |
GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
DE3872872T2 (en) | 1987-11-14 | 1993-02-04 | Beecham Group Plc | 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF CUSHION AND BRONCHO CONSTRUCTION. |
EP0350130A3 (en) | 1988-07-07 | 1991-07-10 | Duphar International Research B.V | New substituted 1,7-annelated 1h-indazoles |
US4895943A (en) | 1988-10-25 | 1990-01-23 | Pfizer Inc. | Preparation of 1,4-diazabicyclo(3.2.2)nonane |
US5223625A (en) | 1988-12-22 | 1993-06-29 | Duphar International Research B.V. | Annelated indolo [3,2,-C]lactams |
EP0377238A1 (en) | 1988-12-22 | 1990-07-11 | Duphar International Research B.V | New annelated indolo (3,2-c)-lactams |
WO1990014347A1 (en) | 1989-05-24 | 1990-11-29 | Nippon Shinyaku Co., Ltd. | Indole derivatives and medicine |
WO1991007402A1 (en) * | 1989-11-17 | 1991-05-30 | Pfizer Inc. | Azabicyclo amides and esters as 5-ht3 receptor antagonists |
US5446050A (en) | 1989-11-17 | 1995-08-29 | Pfizer Inc. | Azabicyclo amides and esters as 5-HT3 receptor antagonists |
GB8928837D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Pharmaceuticals |
US5098889A (en) | 1990-09-17 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
US5192770A (en) | 1990-12-07 | 1993-03-09 | Syntex (U.S.A.) Inc. | Serotonergic alpha-oxoacetamides |
HU211081B (en) | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
WO1992012149A1 (en) | 1991-01-09 | 1992-07-23 | Smithkline Beecham Plc | Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
GB9121835D0 (en) | 1991-10-15 | 1991-11-27 | Smithkline Beecham Plc | Pharmaceuticals |
US5273972A (en) | 1992-03-26 | 1993-12-28 | A. H. Robins Company, Incorporated | [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates |
US5679673A (en) | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
IT1256623B (en) | 1992-12-04 | 1995-12-12 | Federico Arcamone | TACHYCHININ ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION AND USE IN PHARMACEUTICAL FORMULATIONS |
GB9406857D0 (en) | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
SE9600683D0 (en) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
US6624173B1 (en) | 1997-06-30 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions for treating and/or preventing CNS disorders |
FR2769915B1 (en) * | 1997-10-21 | 2000-10-13 | Synthelabo | TRICYCLIC INDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2788982B1 (en) | 1999-02-02 | 2002-08-02 | Synthelabo | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL |
FR2791678B1 (en) | 1999-03-30 | 2001-05-04 | Synthelabo | 1,4-DIAZABICYCLO [3.2.2] NONANE-4-CARBOXYLATES AND -CARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
SE9903760D0 (en) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
JP2004502642A (en) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | Cannabinoid receptor modulators, methods for their production, and use of cannabinoid receptor modulators for the treatment of respiratory and non-respiratory diseases |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
EP1289996B1 (en) | 2000-05-25 | 2005-04-06 | Targacept, Inc. | Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands |
FR2809732B1 (en) | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | DERIVATIVES OF 4 (-2-PHENYLTHIAZOL-5-yl) -1,4-DIAZABICYCLO- [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPY APPLICATION |
JP4616971B2 (en) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1-azabicycloalkane compounds and pharmaceutical uses thereof |
US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
AU2001284646A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002036114A1 (en) | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3 |
US20020086871A1 (en) | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
EP1231212B1 (en) | 2001-02-06 | 2006-12-20 | Pfizer Products Inc. | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
PE20021019A1 (en) | 2001-04-19 | 2002-11-13 | Upjohn Co | SUBSTITUTED AZABYCLE GROUPS |
DE60203007T2 (en) | 2001-06-01 | 2005-07-07 | Neurosearch A/S | HETEROARYL DIAZABICYCLOALKANDERIVATES AS CNS MODULATORS |
EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | Rho KINASE INHIBITORS |
AR036040A1 (en) | 2001-06-12 | 2004-08-04 | Upjohn Co | MULTICICLIC HETEROARYL COMPOUNDS REPLACED WITH QUINUCLIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AR036041A1 (en) | 2001-06-12 | 2004-08-04 | Upjohn Co | HETEROCICLIC AROMATIC COMPOUNDS REPLACED WITH QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CA2460075A1 (en) | 2001-09-12 | 2003-03-20 | Donn Gregory Wishka | Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
ES2383001T3 (en) | 2001-10-02 | 2012-06-15 | Pharmacia & Upjohn Company Llc | Condensed heteroaryl compounds substituted with azabicyclic for the treatment of diseases |
US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
MXPA04003986A (en) | 2001-10-26 | 2004-07-23 | Upjohn Co | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists. |
EP1442037A1 (en) | 2001-11-09 | 2004-08-04 | PHARMACIA & UPJOHN COMPANY | Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands |
DE10156719A1 (en) | 2001-11-19 | 2003-05-28 | Bayer Ag | New N-(aza-bicycloalkyl)-benzo-heterocyclic carboxamides, useful as Alpha-7-nicotinic acetylcholine receptor ligands for e.g. improving attention, concentration, learning and/or memory performance |
DE10162375A1 (en) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclic N-aryl amides |
DE10305922A1 (en) | 2002-06-10 | 2004-03-04 | Bayer Ag | New N-azabicyclooctyl bicyclic heteroaryl carboxamides, are alpha 7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
EP1476448A2 (en) | 2002-02-19 | 2004-11-17 | PHARMACIA & UPJOHN COMPANY | Azabicyclic compounds for the treatment of disease |
AU2003214936A1 (en) | 2002-02-20 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
DE10211415A1 (en) | 2002-03-15 | 2003-09-25 | Bayer Ag | New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance |
ES2197001B1 (en) | 2002-03-26 | 2004-11-16 | Laboratorios Vita, S.A. | PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND. |
EP1506205B1 (en) | 2002-05-07 | 2008-07-16 | Neurosearch A/S | Novel azacyclic ethynyl derivatives |
CA2482639A1 (en) | 2002-05-30 | 2003-12-11 | Neurosearch A/S | 3-substituted quinuclidines and their use |
GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
US20060135516A1 (en) | 2002-08-10 | 2006-06-22 | Astex Technology, Ltd. | 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
SE0202430D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
US20050245567A1 (en) * | 2002-08-14 | 2005-11-03 | Dan Peters | Novel quinuclidine derivatives and their use |
SE0202465D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
PL210065B1 (en) * | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
FR2845388B1 (en) | 2002-10-08 | 2004-11-12 | Sanofi Synthelabo | 1,4-DIAZABICYCLO [3.2.2] NONANECARBOXAMIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US7456171B2 (en) | 2002-10-08 | 2008-11-25 | Sanofi-Aventis | 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof |
KR101176670B1 (en) * | 2004-03-25 | 2012-08-23 | 메모리 파마슈티칼스 코포레이션 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
-
2005
- 2005-12-21 AU AU2005319248A patent/AU2005319248A1/en not_active Abandoned
- 2005-12-21 DE DE602005019094T patent/DE602005019094D1/en active Active
- 2005-12-21 JP JP2007548401A patent/JP2008525464A/en active Pending
- 2005-12-21 CN CNA2005800485590A patent/CN101124224A/en active Pending
- 2005-12-21 WO PCT/US2005/046256 patent/WO2006069097A2/en active Application Filing
- 2005-12-21 PL PL05854897T patent/PL1828179T3/en unknown
- 2005-12-21 BR BRPI0517494-5A patent/BRPI0517494A/en not_active IP Right Cessation
- 2005-12-21 CA CA002591817A patent/CA2591817A1/en not_active Abandoned
- 2005-12-21 AT AT05854897T patent/ATE455776T1/en active
- 2005-12-21 RU RU2007128062/04A patent/RU2418797C2/en not_active IP Right Cessation
- 2005-12-21 ES ES05854897T patent/ES2342675T3/en active Active
- 2005-12-21 KR KR1020077016683A patent/KR20070087674A/en not_active Application Discontinuation
- 2005-12-21 US US11/312,831 patent/US7625924B2/en not_active Expired - Fee Related
- 2005-12-21 EP EP05854897A patent/EP1828179B1/en not_active Not-in-force
- 2005-12-21 MX MX2007007328A patent/MX2007007328A/en active IP Right Grant
-
2009
- 2009-08-31 US US12/551,020 patent/US20100016351A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1828179B1 (en) | 2010-01-20 |
WO2006069097A3 (en) | 2006-10-05 |
MX2007007328A (en) | 2007-07-25 |
US20100016351A1 (en) | 2010-01-21 |
DE602005019094D1 (en) | 2010-03-11 |
US20060167039A1 (en) | 2006-07-27 |
ES2342675T3 (en) | 2010-07-12 |
ATE455776T1 (en) | 2010-02-15 |
CA2591817A1 (en) | 2006-06-29 |
AU2005319248A1 (en) | 2006-06-29 |
EP1828179A2 (en) | 2007-09-05 |
KR20070087674A (en) | 2007-08-28 |
WO2006069097A2 (en) | 2006-06-29 |
JP2008525464A (en) | 2008-07-17 |
BRPI0517494A (en) | 2008-10-14 |
CN101124224A (en) | 2008-02-13 |
RU2418797C2 (en) | 2011-05-20 |
US7625924B2 (en) | 2009-12-01 |
PL1828179T3 (en) | 2010-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007128062A (en) | A-7 NICOTINE RECEPTOR LIGANDS, THEIR PRODUCTION AND APPLICATION | |
JP2008525464A5 (en) | ||
JP6862495B2 (en) | Treatment of B-cell malignancies with a combination of JAK and PI3K inhibitors | |
US10544146B2 (en) | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | |
RU2417225C2 (en) | Indazoles, bentothiazoles, benzoisothiazoles, benzisoxazoles and synthesis and use thereof | |
RU2769607C2 (en) | N-acyl-n'-(pyridin-2-yl)carbamides and their analogues exhibiting anticancer and antiproliferative activity | |
CN107089985B (en) | Pyrrolo- [2,3-D] pyrimidine derivatives as Zhan Nasi associated kinase (JAK) inhibitor | |
CA2499128A1 (en) | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | |
AU2012396338B2 (en) | New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | |
JP6585158B2 (en) | Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase | |
JP2007538011A5 (en) | ||
RU2006143153A (en) | 1H-INDAZOZOLES, BENZOTHYAZOZOLES, 1, 2-BENZISISOXAZOZOLES, 1, 2-BENZISISOTHIAZOLES AND CHROMONES AND THEIR PRODUCTION AND APPLICATIONS | |
US20080166359A1 (en) | Methods of using MEK inhibitors | |
RU2008128570A (en) | [(1H-INDOL-5-IL) -HETERO-Aryloxy] - (azabicyclo [3.3.1] NONANES AS N-ACHR CHOLINERGIC LIGANDS FOR THE TREATMENT OF PSYCHOTIC AND NON-NEUROGENEROGENIC | |
US20140234270A1 (en) | Treatment wth alphat selective ligands | |
WO2012005227A1 (en) | Tetrahydrocarboline derivative | |
CA3036245A1 (en) | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | |
BG106680A (en) | New use and novel n-azabicyclo-amide derivatives | |
JP2005516954A (en) | 1-Alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists | |
RU2006126540A (en) | INDOLES, 1H-INDAZOLES, 1, 2-BENZISOXOXAZOLE AND 1, 2-BENZISOTHYZAZOLE, THEIR PRODUCTION AND APPLICATION | |
JP2007515486A (en) | 3-quinuclidinyl heteroatom bridged biaryl derivatives | |
EP4376840A1 (en) | Substituted pyridine derivatives as sarm1 inhibitors | |
US20220041588A1 (en) | Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
US20190300546A1 (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
JP2007515485A (en) | 3-quinuclidinylamino-substituted biaryl derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20121222 |